
Monday, May 20, 2024 1:37:36 PM
I am not questioning the credibility of the attorney. I do question why they used unaudited financials instead of the audited financials. I don't see how the attorney would be held accountable for this opinion if anything is incorrect.
The opinion and conclusions herein are based upon documentation and facts made available to me by
the Company and are based on the accuracy of those documents and facts. The documentation that
was provided to me was believed to be true and reliable in its contents. Below is the information posted
to the OTC Disclosure and News Service on May 14, 2024 which I have reviewed in rendering this
opinion:
1. Amended Annual Report for the year ended December 31, 2023.
2. Balance Sheet as of the years ended December 31, 2023 and 2022 (unaudited).
3. Statement of Operations for the years ended December 31, 2023 and 2022 (unaudited).
4. Statement of Cash Flows for the years ended December 31, 2023 and 2022 (unaudited).
5. Statement of Stockholders’ Equity for the years ended December 31, 2021 through 2023
(unaudited).
6. Notes to Financial Statements (Unaudited).
I personally met with Steven Sharabura, CEO of the Issuer, to discuss and review the above
documentation. In the event that the facts and information in all such documents are determined not
to be true, this opinion shall be null and void.
https://www.otcmarkets.com/otcapi/company/financial-report/402947/content
A New Mining Model Is Emerging - And Wall Street Is Paying Attention • B • Jul 15, 2025 9:00 AM
Sanwire Files Complaint Against Intercept Music and Trillium Partners • SNWR • Jul 15, 2025 9:00 AM
Cannabix Technologies Commences First Production of BreathLogix Alcohol Screening Devices • BLO • Jul 15, 2025 8:47 AM
Nightfood's FHVH to Pioneer AI-Driven Culinary Education in $32.5 Billion US Market • NGTF • Jul 15, 2025 8:30 AM
The Crypto Company (OTC: CRCW) Joins New OTCID Market Tier, Marking Commitment to Innovation, Transparency, and Strategic Growth • CRCW • Jul 15, 2025 8:19 AM
Avant Technologies and JV Partner, Ainnova, Complete Pivotal Meeting with U.S. FDA • AVAI • Jul 15, 2025 8:00 AM